RxDoctor Payments DataLook up a doctor →

William Caldwell, DO

Pain Medicine · Stony Brook, NYNPI 1487965778

Payments from drug & device makers

$550,063in general payments, 2019–2025

Across 1,482 payments — averaging $371.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$355K
  • Relievant Medsystems, Inc.$143K
  • Medtronic$46K
  • Abbott$2K
  • Nevro Corp.$705
  • Stryker$468
  • plus $3K from 21 others
$345in research payments, 2019–2025

Across 1 payment — averaging $345.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$345

What the payments were for

  • Consulting fees$14,7753%
  • Speaking & faculty fees$439,97783%
  • Travel & lodging$35,5607%
  • Food & beverage$39,7608%
  • Education$500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$550,063 in reported general payments places this provider in the 95th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$1,268,632
Medicare patients
1,006
Services billed
24,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl19$35,131
NucyntaTapentadol Hcl19$32,430
Pregabalin50$1,920
Gabapentin68$989
Oxycodone Hcl96$902
Duloxetine Hcl33$840
Celecoxib36$835
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$706
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen33$668
Tizanidine Hcl38$598
Tramadol Hcl56$281
Methocarbamol20$186
Meloxicam24$113
Methylprednisolone11$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Nucynta$370$67,56138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 pain medicine providers in New York.

Other pain medicine in Stony Brook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →